BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Daws RE, Timmermann C, Giribaldi B, Sexton JD, Wall MB, Erritzoe D, Roseman L, Nutt D, Carhart-harris R. Increased global integration in the brain after psilocybin therapy for depression. Nat Med. [DOI: 10.1038/s41591-022-01744-z] [Cited by in Crossref: 22] [Cited by in F6Publishing: 34] [Article Influence: 22.0] [Reference Citation Analysis]
Number Citing Articles
1 Nutt D, Spriggs M, Erritzoe D. Psychedelics therapeutics: What we know, what we think, and what we need to research. Neuropharmacology 2023;223:109257. [PMID: 36179919 DOI: 10.1016/j.neuropharm.2022.109257] [Reference Citation Analysis]
2 Timmermann C, Bauer PR, Gosseries O, Vanhaudenhuyse A, Vollenweider F, Laureys S, Singer T, Antonova E, Lutz A; Mind and Life Europe (MLE) ENCECON Research Group. A neurophenomenological approach to non-ordinary states of consciousness: hypnosis, meditation, and psychedelics. Trends Cogn Sci 2023;27:139-59. [PMID: 36566091 DOI: 10.1016/j.tics.2022.11.006] [Reference Citation Analysis]
3 Andreassen OA, Hindley GFL, Frei O, Smeland OB. New insights from the last decade of research in psychiatric genetics: discoveries, challenges and clinical implications. World Psychiatry 2023;22:4-24. [PMID: 36640404 DOI: 10.1002/wps.21034] [Reference Citation Analysis]
4 Carlier J, Malaca S, Huestis MA, Tagliabracci A, Tini A, Busardò FP. Biomarkers of 4-hydroxy-N,N-methylpropyltryptamine (4-OH-MPT) intake identified from human hepatocyte incubations. Expert Opin Drug Metab Toxicol 2023;:1-10. [PMID: 36609205 DOI: 10.1080/17425255.2022.2166826] [Reference Citation Analysis]
5 Marwaha S, Palmer E, Suppes T, Cons E, Young AH, Upthegrove R. Novel and emerging treatments for major depression. Lancet 2023;401:141-53. [PMID: 36535295 DOI: 10.1016/S0140-6736(22)02080-3] [Reference Citation Analysis]
6 Johnston JN, Kadriu B, Allen J, Gilbert JR, Henter ID, Zarate CA Jr. Ketamine and serotonergic psychedelics: An update on the mechanisms and biosignatures underlying rapid-acting antidepressant treatment. Neuropharmacology 2023;226:109422. [PMID: 36646310 DOI: 10.1016/j.neuropharm.2023.109422] [Reference Citation Analysis]
7 Mastinu A, Anyanwu M, Carone M, Abate G, Bonini SA, Peron G, Tirelli E, Pucci M, Ribaudo G, Oselladore E, Premoli M, Gianoncelli A, Uberti DL, Memo M. The Bright Side of Psychedelics: Latest Advances and Challenges in Neuropharmacology. Int J Mol Sci 2023;24. [PMID: 36674849 DOI: 10.3390/ijms24021329] [Reference Citation Analysis]
8 Pacheco AT, Olson RJ, Garza G, Moghaddam B. Acute psilocybin enhances cognitive flexibility in rats. bioRxiv 2023:2023. [PMID: 36712091 DOI: 10.1101/2023.01.09.523291] [Reference Citation Analysis]
9 Singewald N, Sartori SB, Reif A, Holmes A. Alleviating anxiety and taming trauma: Novel pharmacotherapeutics for anxiety disorders and posttraumatic stress disorder. Neuropharmacology 2023;226:109418. [PMID: 36623804 DOI: 10.1016/j.neuropharm.2023.109418] [Reference Citation Analysis]
10 Hossain M, Sulochana SP, Heath KE, Bari SMI, Brewster P, Barnes J, Munivar A, Walker GM, Puleo DA, Werfel TA. Interval delivery of 5HT(2A) agonists using multilayered polymer films. J Biomed Mater Res A 2023. [PMID: 36606344 DOI: 10.1002/jbm.a.37497] [Reference Citation Analysis]
11 Malaca S, Bottinelli C, Fanton L, Cartiser N, Carlier J, Busardò FP. α-Methyltryptamine (α-MT) Metabolite Profiling in Human Hepatocyte Incubations and Postmortem Urine and Blood. Metabolites 2023;13. [PMID: 36677017 DOI: 10.3390/metabo13010092] [Reference Citation Analysis]
12 Shao X, Yan D, Kong W, Sun S, Liao M, Ou W, Zhang Y, Zheng F, Li X, Li L, Hu B. Brain function changes reveal rapid antidepressant effects of nitrous oxide for treatment-resistant depression:evidence from task-state EEG. Psychiatry Research 2023. [DOI: 10.1016/j.psychres.2023.115072] [Reference Citation Analysis]
13 Ledwos N, Rodas JD, Husain MI, Feusner JD, Castle DJ. Therapeutic uses of psychedelics for eating disorders and body dysmorphic disorder. J Psychopharmacol 2023;37:3-13. [PMID: 36515406 DOI: 10.1177/02698811221140009] [Reference Citation Analysis]
14 Marguilho M, Figueiredo I, Castro-Rodrigues P. A unified model of ketamine's dissociative and psychedelic properties. J Psychopharmacol 2023;37:14-32. [PMID: 36527355 DOI: 10.1177/02698811221140011] [Reference Citation Analysis]
15 Maia LO, Daldegan-Bueno D, Wießner I, Araujo DB, Tófoli LF. Ayahuasca's therapeutic potential: What we know - and what not. Eur Neuropsychopharmacol 2023;66:45-61. [PMID: 36368095 DOI: 10.1016/j.euroneuro.2022.10.008] [Reference Citation Analysis]
16 Kious B, Schwartz Z, Lewis B. Should we be leery of being Leary? Concerns about psychedelic use by psychedelic researchers. J Psychopharmacol 2023;37:45-8. [PMID: 36377548 DOI: 10.1177/02698811221133461] [Reference Citation Analysis]
17 Gandia A, Adamatzky A. Electrical spiking of psilocybin fungi. Communicative & Integrative Biology 2022;15:226-231. [DOI: 10.1080/19420889.2022.2136118] [Reference Citation Analysis]
18 Carhart-Harris RL, Chandaria S, Erritzoe DE, Gazzaley A, Girn M, Kettner H, Mediano PAM, Nutt DJ, Rosas FE, Roseman L, Timmermann C, Weiss B, Zeifman RJ, Friston KJ. Canalization and plasticity in psychopathology. Neuropharmacology 2022;226:109398. [PMID: 36584883 DOI: 10.1016/j.neuropharm.2022.109398] [Reference Citation Analysis]
19 Moujaes F, Preller KH, Ji JL, Murray JD, Berkovitch L, Vollenweider FX, Anticevic A. Towards mapping neuro-behavioral heterogeneity of psychedelic neurobiology in humans. Biol Psychiatry 2022:S0006-3223(22)01805-4. [PMID: 36715317 DOI: 10.1016/j.biopsych.2022.10.021] [Reference Citation Analysis]
20 Pędzich BD, Medrano M, Buckinx A, Smolders I, De Bundel D. Psychedelic-Induced Serotonin 2A Receptor Downregulation Does Not Predict Swim Stress Coping in Mice. Int J Mol Sci 2022;23. [PMID: 36499610 DOI: 10.3390/ijms232315284] [Reference Citation Analysis]
21 Balodis IM. Converging on Resilience Factors. Biological Psychiatry 2022;92:834-835. [DOI: 10.1016/j.biopsych.2022.09.023] [Reference Citation Analysis]
22 Polityńska B, Pokorska O, Wojtukiewicz AM, Sawicka M, Myśliwiec M, Honn KV, Tucker SC, Wojtukiewicz MZ. Is depression the missing link between inflammatory mediators and cancer? Pharmacol Ther 2022;240:108293. [PMID: 36216210 DOI: 10.1016/j.pharmthera.2022.108293] [Reference Citation Analysis]
23 Dooper M. Fast and sustained effect of 2 administrations of psilocybin on depression. Medicom Conference Report ECNP 2022 2022. [DOI: 10.55788/0629715f] [Reference Citation Analysis]
24 Gotvaldová K, Borovička J, Hájková K, Cihlářová P, Rockefeller A, Kuchař M. Extensive Collection of Psychotropic Mushrooms with Determination of Their Tryptamine Alkaloids. Int J Mol Sci 2022;23. [PMID: 36430546 DOI: 10.3390/ijms232214068] [Reference Citation Analysis]
25 Kwan AC, Olson DE, Preller KH, Roth BL. The neural basis of psychedelic action. Nat Neurosci 2022;25:1407-19. [PMID: 36280799 DOI: 10.1038/s41593-022-01177-4] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
26 Solmi M, Chen C, Daure C, Buot A, Ljuslin M, Verroust V, Mallet L, Khazaal Y, Rothen S, Thorens G, Zullino D, Gobbi G, Rosenblat J, Husain MI, De Gregorio D, Castle D, Sabé M. A century of research on psychedelics: A scientometric analysis on trends and knowledge maps of hallucinogens, entactogens, entheogens and dissociative drugs. European Neuropsychopharmacology 2022;64:44-60. [DOI: 10.1016/j.euroneuro.2022.09.004] [Reference Citation Analysis]
27 Hingorani M, Viviani AML, Sanfilippo JE, Janušonis S. High-resolution spatiotemporal analysis of single serotonergic axons in an in vitro system. Front Neurosci 2022;16. [DOI: 10.3389/fnins.2022.994735] [Reference Citation Analysis]
28 Gobbi G, Inserra A, Greenway KT, Lifshitz M, Kirmayer LJ. Psychedelic medicine at a crossroads: Advancing an integrative approach to research and practice. Transcult Psychiatry 2022;:13634615221119388. [PMID: 36263521 DOI: 10.1177/13634615221119388] [Reference Citation Analysis]
29 Mallaroni P, Mason NL, Kloft L, Reckweg JT, van Oorsouw K, Toennes SW, Tolle HM, Amico E, Ramaekers JG. Ritualistic use of ayahuasca enhances a shared functional connectome identity with others.. [DOI: 10.1101/2022.10.07.511268] [Reference Citation Analysis]
30 Lee C, Zhang Z, Janušonis S. Brain serotonergic fibers suggest anomalous diffusion-based dropout in artificial neural networks. Front Neurosci 2022;16:949934. [DOI: 10.3389/fnins.2022.949934] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 López-arnau R, Camarasa J, Carbó M, Nadal-gratacós N, Puigseslloses P, Espinosa-velasco M, Urquizu E, Escubedo E, Pubill D. 3,4-Methylenedioxy methamphetamine, synthetic cathinones and psychedelics: From recreational to novel psychotherapeutic drugs. Front Psychiatry 2022;13:990405. [DOI: 10.3389/fpsyt.2022.990405] [Reference Citation Analysis]
32 Pasquini L, Fryer SL, Eisendrath SJ, Segal ZV, Lee AJ, Brown JA, Saggar M, Mathalon DH. Dysfunctional cortical gradient topography in treatment resistant major depression. Biological Psychiatry: Cognitive Neuroscience and Neuroimaging 2022. [DOI: 10.1016/j.bpsc.2022.10.009] [Reference Citation Analysis]
33 Hall WD, Humphreys K. Is good science leading the way in the therapeutic use of psychedelic drugs? Psychol Med 2022;52:2849-51. [PMID: 36259413 DOI: 10.1017/S0033291722003191] [Reference Citation Analysis]
34 Erkizia-santamaría I, Alles-pascual R, Horrillo I, Meana J, Ortega J. Serotonin 5-HT2A, 5-HT2c and 5-HT1A receptor involvement in the acute effects of psilocybin in mice. In vitro pharmacological profile and modulation of thermoregulation and head-twich response. Biomedicine & Pharmacotherapy 2022;154:113612. [DOI: 10.1016/j.biopha.2022.113612] [Reference Citation Analysis]
35 Ko K, Kopra EI, Cleare AJ, Rucker JJ. TEMPORARY REMOVAL: Psychedelic therapy for depressive symptoms: Asystematic review and meta-analysis. Journal of Affective Disorders 2022. [DOI: 10.1016/j.jad.2022.09.168] [Reference Citation Analysis]
36 Jaster AM, Younkin J, Cuddy T, de la Fuente Revenga M, Poklis JL, Dozmorov MG, González-Maeso J. Differences across sexes on head-twitch behavior and 5-HT(2A) receptor signaling in C57BL/6J mice. Neurosci Lett 2022;788:136836. [PMID: 35963476 DOI: 10.1016/j.neulet.2022.136836] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
37 Doss MK, Barrett FS, Corlett PR. Skepticism about Recent Evidence That Psilocybin "Liberates" Depressed Minds. ACS Chem Neurosci 2022;13:2540-3. [PMID: 36001741 DOI: 10.1021/acschemneuro.2c00461] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Willyard C. Psychedelic drugs take on depression. Nature 2022;608:S36-8. [DOI: 10.1038/d41586-022-02205-w] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
39 Bogenschutz MP, Ross S, Bhatt S, Baron T, Forcehimes AA, Laska E, Mennenga SE, O'Donnell K, Owens LT, Podrebarac S, Rotrosen J, Tonigan JS, Worth L. Percentage of Heavy Drinking Days Following Psilocybin-Assisted Psychotherapy vs Placebo in the Treatment of Adult Patients With Alcohol Use Disorder: A Randomized Clinical Trial. JAMA Psychiatry 2022. [PMID: 36001306 DOI: 10.1001/jamapsychiatry.2022.2096] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
40 Kranzler HR, Hartwell EE. Treating Alcohol Use Disorder With Hallucinogens-Renewed Interest After a 50-Year Hiatus. JAMA Psychiatry 2022. [PMID: 36001305 DOI: 10.1001/jamapsychiatry.2022.2029] [Reference Citation Analysis]
41 Nour MM, Liu Y, Dolan RJ. Functional neuroimaging in psychiatry and the case for failing better. Neuron 2022;110:2524-44. [PMID: 35981525 DOI: 10.1016/j.neuron.2022.07.005] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
42 Yin YN, Gao TM. Non-hallucinogenic Psychedelic Analog Design: A Promising Direction for Depression Treatment. Neurosci Bull 2023;39:170-2. [PMID: 35927548 DOI: 10.1007/s12264-022-00933-7] [Reference Citation Analysis]
43 Kumar Palepu MS, Dandekar MP. Remodeling of microbiota gut-brain axis using psychobiotics in depression. Eur J Pharmacol 2022;:175171. [PMID: 35926568 DOI: 10.1016/j.ejphar.2022.175171] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
44 Hingorani M, Viviani AM, Sanfilippo JE, Janušonis S. High-Resolution Spatiotemporal Analysis of Single Serotonergic Axons in an In Vitro System.. [DOI: 10.1101/2022.07.16.500161] [Reference Citation Analysis]
45 Vohryzek J, Cabral J, Lord L, Fernandes HM, Roseman L, Nutt DJ, Carhart-harris RL, Deco G, Kringelbach ML. Brain dynamics predictive of response to psilocybin for treatment-resistant depression.. [DOI: 10.1101/2022.06.30.497950] [Reference Citation Analysis]
46 Gandia A, Adamatzky A. Electrical spiking of psilocybin fungi.. [DOI: 10.1101/2022.07.02.498545] [Reference Citation Analysis]
47 McCulloch DE, Knudsen GM, Barrett FS, Doss MK, Carhart-Harris RL, Rosas FE, Deco G, Kringelbach ML, Preller KH, Ramaekers JG, Mason NL, Müller F, Fisher PM. Psychedelic resting-state neuroimaging: A review and perspective on balancing replication and novel analyses. Neurosci Biobehav Rev 2022;138:104689. [PMID: 35588933 DOI: 10.1016/j.neubiorev.2022.104689] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
48 Pasquini L, Fryer SL, Eisendrath SJ, Segal ZV, Lee AJ, Brown JA, Saggar M, Mathalon DH. Dysfunctional cortical gradient topography in treatment resistant major depression.. [DOI: 10.1101/2022.06.16.22276402] [Reference Citation Analysis]
49 Dworkin RH, Anderson BT, Andrews N, Edwards RR, Grob CS, Ross S, Satterthwaite TD, Strain EC. If the doors of perception were cleansed, would chronic pain be relieved? Evaluating the benefits and risks of psychedelics. J Pain 2022:S1526-5900(22)00329-7. [PMID: 35643270 DOI: 10.1016/j.jpain.2022.05.003] [Reference Citation Analysis]
50 Lee C, Zhang Z, Janušonis S. Brain Serotonergic Fibers Suggest Anomalous Diffusion-Based Dropout in Artificial Neural Networks.. [DOI: 10.1101/2022.05.22.492968] [Reference Citation Analysis]
51 Kingwell K. Probing the antidepressant action of psychedelics. Nat Rev Drug Discov 2022. [PMID: 35534611 DOI: 10.1038/d41573-022-00085-3] [Reference Citation Analysis]
52 Sotille R, Singh H, Weisman A, Vida T. Unraveling the Mysteries of Mental Illness With Psilocybin. Cureus 2022;14:e25414. [PMID: 35769681 DOI: 10.7759/cureus.25414] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
53 Marineci CD. Drugs for mood disorders. Farmacist ro 2022;5:6. [DOI: 10.26416/farm.208.5.2022.7143] [Reference Citation Analysis]
54 Kuburi S, Di Passa A, Tassone VK, Mahmood R, Lalovic A, Ladha KS, Dunlop K, Rizvi S, Demchenko I, Bhat V. Neuroimaging Correlates of Treatment Response with Psychedelics in Major Depressive Disorder: A Systematic Review. Chronic Stress 2022;6:247054702211153. [DOI: 10.1177/24705470221115342] [Reference Citation Analysis]